MeiraGTx Holdings plc

MGTX

KYG596651029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/09/2024 BST			5-day change	1st Jan Change
4.070 ^USD	+1.24%		+4.09%	-42.02%

08-13	RBC Adjusts Price Target on MeiraGTx Holdings to $9 From $11, Maintains Outperform Rating, Speculative Risk	MT
08-12	MeiraGTx Holdings Raises $50 Million Offering Led by Sanofi	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about MeiraGTx Holdings plc

RBC Adjusts Price Target on MeiraGTx Holdings to $9 From $11, Maintains Outperform Rating, Speculative Risk	08-13	MT
MeiraGTx Holdings Raises $50 Million Offering Led by Sanofi	08-12	MT
Earnings Flash (MGTX) MEIRAGTX Posts Q2 Revenue $282,000	08-12	MT
MeiraGTx Holdings plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-12	CI
Transcript : MeiraGTx Holdings plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM	06-12
Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	05-15
Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000	05-09	MT
MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board	04-16	CI
MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
North American Morning Briefing : Inflation Data -2-	03-12	DJ
Who are OpenAI's new board members?	03-11	RE
MeiraGTx to Receive $50 Million Milestone Payment from J&J's Janssen Under Bota-Vec Deal	02-13	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	12-21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	12-21	MT
MeiraGTx Holdings Shares Rise on Sale of Remaining Bota-vec Interests to Janssen Pharmaceuticals for Up to $415 Million	12-21	MT
Janssen Pharmaceuticals, Inc. entered into an asset purchase agreement to acquire Assets of MeiraGTx Holdings plc from MeiraGTx Holdings plc for approximately $420 million.	12-20	CI
MeiraGTx Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
MeiraGT Receives $30 Million Strategic Investment from Sanofi; to Seek Further Strategic Opportunities	30/10/23	MT
MeiraGTx Gets $30 Million Investment From Sanofi	30/10/23	DJ
Top Premarket Gainers	30/10/23	MT
MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.	29/10/23	CI
MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress	24/10/23	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/08/23	DJ
RBC Cuts Price Target on MeiraGTx Holdings to $11 From $13, Keeps Outperform Rating, Speculative Risk Qualifier	11/08/23	MT

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Employees

387

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company